The Pharma Data

JUNE 15, 2025

Furthermore, Intellia plans to submit a biologics license application (BLA) in 2026 in support of a potential U.S. launch in 2027 — a significant milestone in its mission to bring forward a one-time, potentially curative treatment for hereditary angioedema.

Treatment 40

Treatment Therapies Licensing Licensing 40

BioPharma Drive: Drug Pricing

JUNE 26, 2025

Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. Data from that trial is expected in 2027. “I and European drugmakers.

Disease 109

Disease Licensing Licensing Therapies 109

BioPharma Drive: Drug Pricing

JULY 16, 2025

Published July 16, 2025 • Updated 2 hours ago Ben Fidler Senior Editor post share post print email license Sarepta Therapeutics announced a workforce reduction on July 16, 2025. The company also has $1 billion in senior notes coming due in 2027.

Therapies 301

Therapies FDA Clinical Trials Licensing 301

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Published June 27, 2025 By BioPharma Dive staff post share post print email license Daniel Tadevosyan via Getty Images Today, a brief rundown of news involving Biocryst and Peter Marks, as well as updates from UCB and Altimmune that you may have missed. An oral solution of fenfluramine is already cleared in the U.S.

Vaccine 130

Vaccine FDA Therapies Licensing 130

The Pharma Data

SEPTEMBER 7, 2021

5.500% Notes due 2027. 3.100% Notes due 2027. In any jurisdiction where the laws require the tender offer to be made by a licensed broker or dealer, the tender offer will be deemed made on behalf of Lilly by the dealer managers, or one or more registered brokers or dealers under the laws of such jurisdiction. 284,112,000.

Licensing 52

Licensing Licensing Marketing 52

The Pharma Data

JANUARY 26, 2021

billion by 2027. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. An estimated 700,000 people are diagnosed with HCC each year, with the global market for liver cancer drugs expected to grow to $3.9 About Q BioMed Inc.

Treatment 40

Treatment FDA Small Molecule Drugs 40

Agency IQ

AUGUST 25, 2023

The most recent reauthorization, BsUFA III, extended the program for fiscal years 2023 through 2027, and was authorized at the end of 2022. In these cases, “such text should be written in a manner that does not imply” that the biosimilar product is licensed for these additional use(s).

Biosimilars 40

Biosimilars FDA Production Licensing 40